2016 Fiscal Year Final Research Report
Roles of angiocrine factor signaling in the pathogenesis of leukemia/lymphoma
Project/Area Number |
26461415
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Juntendo University |
Principal Investigator |
HATTORI KOICHI 順天堂大学, 医学(系)研究科(研究院), 特任先任准教授 (10360116)
|
Co-Investigator(Renkei-kenkyūsha) |
Takahashi Satoshi 東京大学, 医科学研究所・幹細胞治療センター, 准教授 (60226834)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | 血液腫瘍学 / 血液内科学 / 生体分子 / 細胞・組織 / 血管新生 |
Outline of Final Research Achievements |
Angiocrine factors released from endothelial cells directly can regulate hematopoiesis and leukemia/lymphoma growth. The serine protease tissue type plasminogen activator, a classical fibrinolytic factor, its endogenous inhibitor plasminogen activator inhibitor-1 and its downstream targets matrix metalloproteases can be released from endothelial cells, and therefore also can be regarded as angiocrine factors. We could show that angiocrine factors regulate leukemia/lymphoma growth and control inflammatory diseases, thereby preventing tissue damage, and disease-associated death in murine models of inflammation. Our recent studies demonstrate that pharmacological and genetic control of the fibrinolytic system is a new therapeutic approach to treat inflammation-associated leukemia/lymphoma and associated diseases. Therefore, the initially proposed action plan for this research was performed as proposed and the targets achieved.
|
Free Research Field |
血液内科学
|